Answers are grounded in this paper and cite their sources.
Understanding patient preferences is important for facilitating informed decision-making in managing patients with inflammatory bowel disease (IBD). This study explored the preferences of patients with Crohn’s disease (CD) and ulcerative colitis (UC) regarding advanced therapy treatment attributes in five non-Western countries: Argentina, Australia, Brazil, Saudi Arabia and Taiwan. Adult patients with self-reported CD or UC treated for ≥ 6 months participated in this cross-sectional online survey. A discrete choice experiment assessed the relative importance of treatment attributes using conditional logit models. The primary objective was to estimate partworth utilities across the five countries (overall population). Overall, 706 patients with CD and UC (n = 353 each) completed the survey (mean age 36.8 and 37.7 years; female 47.9% and 47.6%; mean disease duration 4.5 and 4.6 years, respectively). For patients with CD, the rate of long-term remission on maintenance therapy (LTREM) was the most preferred treatment attribute (32.5%), followed by the rate of 1-year remission (25.7%), routes of administration (RoAs; 24.6%) and risk of serious adverse events (AEs) (11.5%) and mild AEs (5.8%). For patients with UC, the rate of corticosteroid-free remission after 1 year was the most important attribute (30.8%), followed by RoAs (27.4%), rate of mucosal healing after 1 year (16.1%), LTREM (14.9%) and risk of serious AEs (10.0%) and mild AEs (0.8%). Patients in both groups considered abdominal pain as the symptom most impacting their quality of life. Approximately half of the patients (CD 49.3%; UC 50.5%) exposed to advanced therapy indicated that they would have preferred to start advanced therapy earlier. Patients with IBD from non-Western countries prioritised advanced treatment attributes such as efficacy outcomes and RoAs, although treatment preferences varied between patients with CD and UC. Shared decision-making between patients and physicians regarding advanced therapy choice and timing should occur throughout the treatment journey. Understanding what patients prioritize in their treatment options helps doctors make better decisions and improve care. Most studies on treatment preferences in inflammatory bowel disease, specifically Crohn’s disease (CD) and ulcerative colitis (UC), have focused on Western countries, leaving a gap in knowledge about how patients in other parts of the world think about and prioritise aspects of their care. This study explored the treatment preferences of patients with CD and UC for advanced therapies, from five non-Western countries: Argentina, Australia, Brazil, Saudi Arabia and Taiwan. A total of 706 patients with CD and UC were included; they were asked to complete an online survey about the different factors that influence their choice of treatment. These factors included how well a treatment works (e.g. long-term remission), route of administration (e.g. by injection, oral medication) and the risks of side effects. Though preferences varied between CD and UC, both groups of patients considered long-term remission and route of administration to be more important than the risk of side effects. Patients with CD mostly cared about long-term remission and the chance of remission after 1 year, while patients with UC prioritized achieving corticosteroid-free remission after 1 year and route of administration. In summary, findings from this study helps us understand the specific preferences that patients with inflammatory bowel disease in non-Western countries have, which should be considered in their treatment plans. It emphasizes the need for ongoing conversations between patients and doctors to ensure treatments meet patients’ needs and expectations.
No takes yet. Share an insight, caveat, or question.
ARGOLLO et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: